Literature DB >> 27261608

Tumor suppressor microRNAs: Targeted molecules and signaling pathways in breast cancer.

F Asghari1, N Haghnavaz1, B Baradaran1, M Hemmatzadeh1, T Kazemi2.   

Abstract

Breast cancer is the most common type of cancer in women whose prevalence is increasing every year. Common strategies for diagnosis, prognosis and specific treatment of breast cancer need improvements to increase patients' survival. For this reason, there is growing number of efforts world-wide with molecular approaches. With the advent of microRNAs (miRNAs), they have been interested for almost all aspects of tumorgenesis and correlation of breast cancer and microRNAs was discovered for the first time in 2005. MiRNAs form a group of small noncoding RNAs which participate in regulation of gene expression and subsequently several biological processes and pathogenesis of various diseases. As other cancers, miRNAs involved in breast cancer are classified in two groups: the first group is tumor inducing miRNAs (also called oncomirs) that can induce tumor initiation and progression, and their expression is increased in cancerous cells. The second group is tumor suppressor miRNAs. In normal situation, tumor suppressor miRNAs prevent beginning and progression of breast cancer through suppressing the expression of various oncogenes. In this review we will give a general overview about miRNAs and breast cancer, and in the following, more discussion about tumor suppressor miRNAs, with focus on the best known of them and their targeted oncogenes and signaling pathways. Finally, we will point to application of this group of miRNAs in diagnosis, prognosis and treatment of patients.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Breast cancer; Signaling pathways; Tumor suppressor; miRNA

Mesh:

Substances:

Year:  2016        PMID: 27261608     DOI: 10.1016/j.biopha.2016.04.011

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  13 in total

Review 1.  Role of MicroRNA Regulation in Obesity-Associated Breast Cancer: Nutritional Perspectives.

Authors:  Ravi Kasiappan; Dheeran Rajarajan
Journal:  Adv Nutr       Date:  2017-11-15       Impact factor: 8.701

2.  MicroRNA-590-3p inhibits invasion and metastasis in triple-negative breast cancer by targeting Slug.

Authors:  Meisi Yan; Leiguang Ye; Xinxin Feng; Runze Shi; Zhen Sun; Zhigao Li; Tong Liu
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

3.  Targeting PDK4 inhibits breast cancer metabolism.

Authors:  Maheedhara R Guda; Swapna Asuthkar; Collin M Labak; Andrew J Tsung; Ilya Alexandrov; Malcolm J Mackenzie; Durbaka Vr Prasad; Kiran K Velpula
Journal:  Am J Cancer Res       Date:  2018-09-01       Impact factor: 6.166

4.  Tumor suppressor function of miR-483-3p on breast cancer via targeting of the cyclin E1 gene.

Authors:  Xiaoxi Huang; Jin Lyu
Journal:  Exp Ther Med       Date:  2018-07-23       Impact factor: 2.447

5.  Long non-coding RNAs XIST and MALAT1 hijack the PD-L1 regulatory signaling pathway in breast cancer subtypes.

Authors:  Amany Samir; Reda Abdel Tawab; Hend M Eltayebi
Journal:  Oncol Lett       Date:  2021-06-07       Impact factor: 2.967

Review 6.  The Role of miRNAs in Common Inflammatory Arthropathies: Osteoarthritis and Gouty Arthritis.

Authors:  Panagiota Papanagnou; Theodora Stivarou; Maria Tsironi
Journal:  Biomolecules       Date:  2016-11-11

7.  Hsa-miR-599 suppresses the migration and invasion by targeting BRD4 in breast cancer.

Authors:  Yonghui Wang; Yana Sui; Qinwei Zhu; Xiaomei Sui
Journal:  Oncol Lett       Date:  2017-07-21       Impact factor: 2.967

8.  LncRNA SNHG12 ameliorates brain microvascular endothelial cell injury by targeting miR-199a.

Authors:  Fa-Qing Long; Qing-Jie Su; Jing-Xia Zhou; De-Sheng Wang; Peng-Xiang Li; Chao-Sheng Zeng; Yi Cai
Journal:  Neural Regen Res       Date:  2018-11       Impact factor: 5.135

9.  MiR-124-3p/B4GALT1 axis plays an important role in SOCS3-regulated growth and chemo-sensitivity of CML.

Authors:  Yu-Xiao Liu; Li Wang; Wen-Jia Liu; Hai-Tao Zhang; Jing-Hui Xue; Zhi-Wen Zhang; Chun-Ji Gao
Journal:  J Hematol Oncol       Date:  2016-08-12       Impact factor: 17.388

Review 10.  Covalent Strategies for Targeting Messenger and Non-Coding RNAs: An Updated Review on siRNA, miRNA and antimiR Conjugates.

Authors:  Santiago Grijalvo; Adele Alagia; Andreia F Jorge; Ramon Eritja
Journal:  Genes (Basel)       Date:  2018-02-06       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.